In combination with anticancer drugs, there was no substantial difference between the effects of ixabepilone and APS on tumor suppression in combination with PD-1 inhibitors, suggesting that APS prevented tumorigenesis or progression in the presence of increased T-cell activation, enhancing the synergistic effect with anti-PD-L1 [138]. Here, CD274 is linked to neoplasm.